Price to Earnings (P/E)
since 2012
Calculation
Zoetis Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income attributable to Zoetis1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | 35.84 | = | 183.49 | ÷ | 5.12 | 5.12 | = | 2,344 | ÷ | 457,867,115 | |
| Feb 14, 2023 | 37.68 | = | 171.90 | ÷ | 4.56 | 4.56 | = | 2,114 | ÷ | 463,386,716 | |
| Feb 15, 2022 | 45.82 | = | 197.76 | ÷ | 4.32 | 4.32 | = | 2,037 | ÷ | 471,970,580 | |
| Feb 16, 2021 | 48.25 | = | 166.32 | ÷ | 3.45 | 3.45 | = | 1,638 | ÷ | 475,166,373 | |
| Feb 13, 2020 | 45.89 | = | 144.94 | ÷ | 3.16 | 3.16 | = | 1,500 | ÷ | 474,933,945 | |
| Feb 14, 2019 | 28.68 | = | 85.54 | ÷ | 2.98 | 2.98 | = | 1,428 | ÷ | 478,771,915 | |
| Feb 15, 2018 | 44.09 | = | 78.50 | ÷ | 1.78 | 1.78 | = | 864 | ÷ | 485,253,713 | |
| Feb 16, 2017 | 31.63 | = | 52.78 | ÷ | 1.67 | 1.67 | = | 821 | ÷ | 491,964,064 | |
| Feb 24, 2016 | 62.14 | = | 42.37 | ÷ | 0.68 | 0.68 | = | 339 | ÷ | 497,155,532 | |
| Feb 27, 2015 | 39.59 | = | 46.09 | ÷ | 1.16 | 1.16 | = | 583 | ÷ | 500,787,817 | |
| Mar 26, 2014 | 29.02 | = | 29.21 | ÷ | 1.01 | 1.01 | = | 504 | ÷ | 500,729,429 | |
| Mar 28, 2013 | 38.30 | = | 33.40 | ÷ | 0.87 | 0.87 | = | 436 | ÷ | 500,000,000 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Zoetis Inc. Annual Report.
Comparison to Competitors
Zoetis Inc., P/E, long-term trends, comparison to competitors
| Zoetis Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | 35.84 | 63.84 | 23.14 | 12.27 | 39.09 | 135.24 | 16.17 | 10.73 | 893.99 | — | 73.42 | 25.99 | 35.65 |
| Feb 14, 2023 | 37.68 | 22.62 | 19.56 | 23.97 | 25.65 | 50.08 | 22.68 | 22.97 | 19.21 | 6.43 | 7.58 | 19.68 | 30.55 |
| Feb 15, 2022 | 45.82 | 22.07 | 21.05 | 20.92 | 29.94 | 40.66 | 12.36 | 20.93 | 14.78 | 5.00 | 11.76 | 8.37 | 27.35 |
| Feb 16, 2021 | 48.25 | 40.17 | 18.82 | — | 44.49 | 31.95 | 641.48 | 28.92 | 26.72 | — | 19.62 | 15.09 | 27.89 |
| Feb 13, 2020 | 45.89 | 17.82 | 17.07 | 41.99 | 38.34 | 16.19 | 16.45 | 25.99 | 20.60 | — | 11.63 | 19.86 | 33.36 |
| Feb 14, 2019 | 28.68 | 20.60 | 14.01 | 16.81 | 29.77 | 39.13 | 15.26 | 23.74 | 33.46 | — | 21.58 | 18.17 | 35.19 |
| Feb 15, 2018 | 44.09 | 35.47 | 64.06 | 103.55 | 27.25 | — | 22.75 | 268.10 | 61.63 | — | 9.99 | 28.99 | 37.66 |
| Feb 16, 2017 | 31.63 | 16.54 | 16.03 | 20.56 | 23.02 | 32.39 | 6.83 | 20.08 | 46.14 | — | 28.10 | 42.64 | 30.45 |
| Feb 24, 2016 | 62.14 | 17.01 | 15.95 | 64.22 | 17.85 | 33.35 | 6.75 | 18.80 | 31.64 | — | 26.37 | 60.50 | 26.19 |
| Feb 27, 2015 | 39.59 | 55.08 | 22.96 | 49.80 | 23.69 | 33.06 | 12.85 | 17.15 | 13.94 | — | 23.03 | 118.44 | 27.26 |
| Mar 26, 2014 | 29.02 | 19.64 | 18.69 | 35.01 | 19.74 | 13.88 | 42.00 | 18.72 | 37.83 | — | 9.32 | 77.00 | 38.43 |
| Mar 28, 2013 | 38.30 | 11.51 | 15.68 | 30.56 | 17.73 | 14.99 | 25.20 | 19.64 | 20.94 | — | 13.51 | 21.42 | 22.54 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Zoetis Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Zoetis Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2024 | 35.84 | 35.36 |
| Feb 14, 2023 | 37.68 | 19.24 |
| Feb 15, 2022 | 45.82 | 17.76 |
| Feb 16, 2021 | 48.25 | 37.29 |
| Feb 13, 2020 | 45.89 | 20.82 |
| Feb 14, 2019 | 28.68 | 23.13 |
| Feb 15, 2018 | 44.09 | 34.49 |
| Feb 16, 2017 | 31.63 | 20.28 |
| Feb 24, 2016 | 62.14 | 18.89 |
| Feb 27, 2015 | 39.59 | 20.74 |
| Mar 26, 2014 | 29.02 | 19.10 |
| Mar 28, 2013 | 38.30 | 17.34 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
Zoetis Inc., P/E, long-term trends, comparison to industry (health care)
| Zoetis Inc. | Health Care | |
|---|---|---|
| Feb 13, 2024 | 35.84 | 30.09 |
| Feb 14, 2023 | 37.68 | 314,676.00 |
| Feb 15, 2022 | 45.82 | 19.87 |
| Feb 16, 2021 | 48.25 | 29.50 |
| Feb 13, 2020 | 45.89 | 21.10 |
| Feb 14, 2019 | 28.68 | 25.51 |
| Feb 15, 2018 | 44.09 | 29.68 |
| Feb 16, 2017 | 31.63 | 21.38 |
| Feb 24, 2016 | 62.14 | 19.10 |
| Feb 27, 2015 | 39.59 | 20.89 |
| Mar 26, 2014 | 29.02 | 18.14 |
| Mar 28, 2013 | 38.30 | 15.43 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).